Extracellular Vesicle Assays for Early Alpha-Synuclein Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for protein misfolding neurodegenerative disorders like Parkinson's disease and dementia with Lewy bodies are unreliable, invasive, and time-consuming, making early detection challenging.
Innovation Solution
The use of extracellular vesicle samples, particularly through size exclusion chromatography, to detect pathological alpha-synuclein and other prion-like proteins, enabling rapid and sensitive assays like RT-QuIC or PMCA for early identification and monitoring of these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If neurological and neuropsychiatric evaluation is used for diagnosis, then diagnostic accuracy is improved, but diagnostic time and complexity increase
Solution Approach 1:
The patent applies preliminary action by detecting pathological protein aggregates in CSF samples before clinical symptoms appear. The method identifies disease markers (alpha-synuclein, tau, amyloid-beta) in the prodromal stage, enabling early diagnosis and intervention before full clinical manifestation occurs, thus reducing overall diagnostic time while maintaining accuracy
Solution Approach 2:
The patent uses CSF samples as an intermediary medium to detect disease markers. Instead of directly evaluating neurological function through complex clinical assessments, the method analyzes protein aggregates in CSF as intermediate indicators that correlate with disease presence and progression, simplifying the diagnostic process while maintaining accuracy
2Reliability
If specialized clinical settings with repeated attendance are used, then diagnostic reliability is improved, but accessibility and ease of operation worsen
Solution Approach 1:
The patent extracts the diagnostic function from specialized clinical settings by identifying specific protein markers (alpha-synuclein, tau, amyloid-beta) in CSF samples that can be analyzed using standardized assays. This extraction allows diagnosis to be performed in routine clinical laboratories rather than requiring repeated attendance at specialized centers, improving accessibility while maintaining reliability through marker-specific detection
Solution Approach 2:
The patent creates a copy of the diagnostic capability by using CSF biomarker analysis that replicates the diagnostic information obtained from complex neurological evaluations. The protein aggregate markers in CSF serve as a surrogate copy of brain pathology, enabling diagnosis to be performed anywhere CSF analysis is available without requiring specialized clinical infrastructure
3Measurement precision
If invasive procedures are used for sample collection, then measurement precision is improved, but patient comfort and ease of operation worsen
Solution Approach 1:
The patent uses CSF as an intermediary fluid that can be collected through lumbar puncture to access brain-derived protein markers. While lumbar puncture is invasive, it provides access to CSF which contains protein aggregates from the central nervous system, serving as a mediator between brain pathology and detectable markers. The method balances invasiveness with detection sensitivity by targeting specific protein markers in CSF that are highly indicative of disease
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable, less invasive, and more sensitive means to detect and monitor protein misfolding disorders before clinical symptoms appear, potentially reducing diagnostic delays and treatment costs.
Implementation Method 1
The use of extracellular vesicle samples, particularly through size exclusion chromatography
Implementation Method 2
enabling rapid and sensitive assays like RT-QuIC or PMCA for early identification and monitoring of these disorders
Data Source
AI summary
The present invention provides novel methods of identifying, monitoring or determining the risk of developing a protein misfolding neurodegenerative disorder in a subject, particularly an alpha synucleinopathy (including Parkinson's disease and dementia with Lewy bodies) using extracellular vesicle samples. Corresponding methods for selecting a treatment and assaying for the presence of a pathological prion-like protein (or one or more ceramide species) in an extracellular vesicle sample are also provided.